Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 11/20 | 0.72 |
| ▸ | CDK2 | P24941 | 11/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.72 |
| ▸ | AURKA | O14965 | 9/20 | 0.72 |
| ▸ | EP300 | Q09472 | 7/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918214 | 0.91 | CCNA2 (0.59) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2919793 | 0.88 | CCNA2 (0.56) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2916155 | 0.87 | CCNA2 (0.56) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2918881 | 0.86 | CDK2 (0.69) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2921951 | 0.85 | AURKA (0.58) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2917938 | 0.84 | CCNA2 (0.51) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2918082 | 0.84 | CCNA2 (0.51) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2915176 | 0.84 | AURKA (1.00) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2923243 | 0.84 | CCNA2 (0.52) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2922678 | 0.83 | AURKA (0.75) | CCNA2CDK2CCNA1AURKAEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| EP-0533047-B1 | Preparation of a cephalosporin antibiotic using the synisomer of a thiazolyl intermediate | BRISTOL MYERS SQUIBB CO (US) | 2003-05-07 | — | — | EP | claimed |
| EP-1084130-B1 | SUBSTITUTED FIVE MEMBERED HETEROCYCLIC COMPOUNDS, FUNGICIDAL COMPOSITIONS CONTAINING THEM AND METHODS OF MANUFACTURE THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2002-09-04 | — | — | EP | claimed |
| EP-0585165-B1 | Process for the preparation of acyl isocyanates | POUDRES & EXPLOSIFS STE NALE (FR) | 1997-06-04 | — | — | EP | claimed |
| WO-2023213445-A1 | METHOD FOR PREPARING 4-[5-[BIS(2-CHLOROETHYL)AMINO]-1-METHYL-1H-BENZO[D]IMIDAZOL-2-YL]BUTYRIC ACID ALKYL ESTERS AND FORMYLATED DERIVATIVES | Heraeus Deutschland GmbH & Co. KG (DE) | 2023-11-09 | — | — | WO | disclosed |
| EP-2766450-B1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | FRAUNHOFER GES FORSCHUNG (DE) | 2018-12-12 | — | — | EP | disclosed |
| EP-2802627-B1 | PARTICULATE SOLID, PROCESS FOR THE PRODUCTION THEREOF, USE AS FILLER AND ASSOCIATED ARTICLES | EVONIK DEGUSSA GMBH (DE) | 2018-05-23 | — | — | EP | disclosed |
| EP-2802627-A1 | PARTICULATE SOLID, PROCESS FOR THE PRODUCTION THEREOF, USE AS FILLER AND ASSOCIATED ARTICLES | Evonik Industries AG (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2766450-A1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. (DE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013104497-A1 | PARTICULATE SOLID, PROCESS FOR THE PRODUCTION THEREOF, USE AS FILLER AND ASSOCIATED ARTICLES | EVONIK INDUSTRIES AG (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013053752-A1 | SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2013-04-18 | — | — | WO | disclosed |
| EP-0360163-A2 | Aromatic carboxylic-acid derivatives and their use in combating the growth of undesirable plants | BASF Aktiengesellschaft (DE) | 1990-03-28 | — | — | EP | disclosed |
| EP-0346789-A2 | Salicylic-acid derivatives and their sulfur analogues | BASF Aktiengesellschaft (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0302491-A1 | 5-Formyl-isoxazoles | BASF Aktiengesellschaft (DE) | 1989-02-08 | — | — | EP | disclosed |
| EP-0044442-B1 | N-(4-PHENYL-2-THIAZOLYL)-OXAMIDIC-ACID-2-ETHOXYETHYLESTER, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THIS COMPOUND | BASF Aktiengesellschaft (DE) | 1984-02-15 | — | — | EP | disclosed |
| EP-0044442-A1 | N-(4-Phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound | BASF Aktiengesellschaft (DE) | 1982-01-27 | — | — | EP | disclosed |
| EP-0009658-B1 | PROCESS FOR THE PREPARATION OF OXALYL CHLORIDE | BAYER AG (DE) | 1981-08-26 | — | — | EP | disclosed |
| EP-0009658-A1 | Process for the preparation of oxalyl chloride | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CCNA2 848/4885CDK2 43/4885CCNA1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.